IGHE
ENSG00000211891
Target class
Secreted protein
Chromosome
14
Approved drugs
1
Clinical candidates (approved and in development)
6
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- IGHE
- Gene name
- Immunoglobulin heavy constant epsilon
- Gene symbol
- IGHE
- Protein name
- Immunoglobulin heavy constant epsilon (Ig epsilon chain C region) (Ig epsilon chain C region ND)
- Gene biotype
- Immunoglobulin constant chain gene
- Gene family
- Immunoglobulin heavy locus at 14q32.33
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 3
- Highest tissue expression
- 4.02
- Tissue specificity (Gini)
- 0.889
- Tissue specificity (tau)
- 0.966
- R-HSA-2454202
- R-HSA-2730905
- R-HSA-2871796
- R-HSA-2871809
- R-HSA-2871837
- R-HSA-6785807
- End position
- 105601728
- Start position
- 105597691
- Chromosome
- 14
- Strand
- Reverse
- [Isoform 1]: Secreted .
- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane
- Single-pass type I membrane protein .
- SUBCELLULAR LOCATION: [Isoform 3]: Cell membrane
- Single-pass type I membrane protein .
- PubMed 7995941
- PubMed 20458139
- PubMed 8976175
- Tissue specificity (tau)
- 0.966066
- Expression inequality (Gini)
- 0.888938
Expression in transcripts per million
- Spleen
- 4.02
- Thyroid
- 1.91
- Small Intestine - Terminal Ileum
- 1.66
- Cells - EBV-transformed lymphocytes
- 0.74
- Whole Blood
- 0.7
Expression in transcripts per million
- Spleen4.02
- Thyroid1.91
- Small Intestine - Terminal Ileum1.66
- Cells - EBV-transformed lymphocytes0.74
- Whole Blood0.7
- Colon - Transverse0.47
- Esophagus - Mucosa0.41
- Stomach0.39
- Lung0.23
- Minor Salivary Gland0.22
- Liver0.1
- Testis0.09
- Cervix - Ectocervix0.07
- Adipose - Visceral (Omentum)0.05
- Kidney - Medulla0.05
- Vagina0.04
- Artery - Coronary0.03
- Breast - Mammary Tissue0.03
- Kidney - Cortex0.03
- Cervix - Endocervix0.01
- Brain - Caudate (basal ganglia)0
- Brain - Anterior cingulate cortex (BA24)0
- Brain - Cortex0
- Pancreas0
- Brain - Cerebellum0
And 29 more, listed on the interactive page.
- GO:0005576
- GO:0005886
- GO:0005515
- GO:0034987
Related records
Trials (220)
- A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
- A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps
- A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy
- A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma
- A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
- A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases
- A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases
- A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
- A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
- A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
- A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma
- A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
- A Prospective Study on Optimizing Treatment for ABPA
- A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)
- A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
- A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines
- A Safety and Efficacy Study of Xolair in Peanut Allergy
- A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
- A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
- A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases
Drugs (6)
- AL-901 Ig epsilon chain C region inhibitor
- Ligelizumab Ig epsilon chain C region inhibitor
- MEDI-4212 Ig epsilon chain C region inhibitor
- Omalizumab Ig epsilon chain C region inhibitor
- Quilizumab Ig epsilon chain C region inhibitor
- Talizumab Ig epsilon chain C region inhibitor